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BACKGROUND AND OBJECTIVES: There are 
few data in the literature on intestinal constipation se-
condary to morphine in cancer patients. This study ai-
med at evaluating intestinal habits of cancer patients 
under morphine.
METHOD: This is a prospective non-randomized study 
carried out from February to November 2007. All pa-
tients had cancer, over 4 years of age and were under 
morphine for pain control. Patients received laxatives 24 
hours after starting with morphine. Intestinal habits were 
evaluated through a structured questionnaire. When nee-
ded, feces were rectally or orally desimpacted. 
RESULTS: Twenty-two cancer patients aged betwe-
en 5 and 35 years (mean 16.7 years) were admitted, 
of whom 63.6% were under palliative care. During 
the first week under morphine and lactulose, 40.9% 
of patients were constipated. In the second and third 
weeks, constipation was present in 38.8% and 16.6% 
of patients, respectively. Treatment was able to control 
constipation in 50% of cases.
CONCLUSION: Constipation was frequent however 
the specific attention to their intestinal habits has increa-
sed adherence to laxatives and has decreased the forma-
tion of fecal impaction. 
Keywords: Intestinal constipation, Pain, Morphine, Ne-
oplasia. 
RESUMO 
JUSTIFICATIVA E OBJETIVOS: Há poucos dados 
na literatura sobre constipação intestinal secundária ao 
uso de morfina em pacientes com câncer. O objetivo des-
te estudo foi avaliar o hábito intestinal de pacientes com 
câncer em uso de morfina.
MÉTODO: Estudo prospectivo, não aleatório, reali-
zado no período de fevereiro a novembro de 2007. To-
dos os pacientes tinham câncer, idade superior a qua-
tro anos e utilizavam morfina para o controle de dor. 
Após 24h do início da morfina os pacientes receberam 
laxantes. A avaliação do hábito intestinal foi realizada 
através de um questionário estruturado. Quando ne-
cessário, foi realizado desimpactação das fezes por 
via retal ou oral. 
RESULTADOS: Foram admitidos 22 pacientes com 
câncer e idade entre cinco e 35 anos (média 16,7 anos), 
dos quais 63,6% estavam em cuidados paliativos. Na 
primeira semana do uso de morfina e lactulona, 40,9% 
dos pacientes ficaram constipados. Na segunda e tercei-
ra semanas, a constipação ocorreu em 38,8% e 16,6%, 
respectivamente. Com o tratamento adotado foi possível 
controlar o quadro de constipação em 50% dos casos. 
CONCLUSÃO: A constipação intestinal foi frequente; 
entretanto, a atenção específica ao hábito intestinal des-
tes pacientes aumentou a adesão aos laxantes e reduziu a 
formação do fecaloma. 
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Descritores: Constipação intestinal, Dor, Morfina, 
Neoplasia.
INTRODUCTION
Pain is common in cancer patients and is considered the 
most prevalent and disabling symptom in this popula-
tion, especially in case of metastases or relapses1,2. The 
World Health Organization (WHO) indicates morphine 
to treat moderate to severe pain of cancer patients3. Ho-
wever, although effective, the treatment with morphine 
is often associated to side effects, such as constipation4,5.
There are few data in the literature about constipation 
secondary to morphine among pediatric cancer patients. 
This symptom is more commonly studied in adults6. Ho-
wever, after studying adverse morphine effects in 122 
Brazilian cancer children7, authors have observed that 
72.9% of cases had constipation. Although being a rela-
tively common manifestation in patients under opioids, 
it is worsened by several other factors such as malnutri-
tion, dehydration and simultaneous use of other drugs, 
which are especially present in metastatic oncologic pa-
tients under palliative care8.
Constipation is a challenge for the oncologic practice 
because it is often neglected by health professionals 
and caregivers, although being associated to several 
other symptoms, such as discomfort, abdominal pain, 
nausea, vomiting, fecal impaction with or without anal 
injury4,5, which invariably impact global health and 
quality of life of cancer patients, in addition to incre-
asing the use of other drugs for relief or symptomatic 
treatment of symptoms and the rate of complications 
and costs related to such interventions.
Considering the relevance of the subject and that expe-
rience in the treatment of opioid-induced constipation in 
children is scarce, this study aimed at evaluating intesti-
nal habits of cancer patients under morphine.
METHOD
Prospective, cohort, non randomized, single-armed stu-
dy carried out from February to November 2007 with 
cancer patients followed by the pain outpatient clinic, 
Pediatric Oncology Institute (IOP), Federal University 
of São Paulo-SP. Participated in this study cancer pa-
tients under morphine for at least one week, indicated 
to control baseline cancer-related pain, with at least four 
years of age. Patients with clinical instability were ex-
cluded. The Free and Informed Consent Term was obtai-
ned from all patients/ guardians.
The intestinal habit of patients included in the study was 
evaluated before admission to the study, 72 hours after 
admission and then in weeks 1, 2 and 3, depending on 
the time they remained under the analgesic.
According to literature criteria, constipation was con-
sidered when: hard stools elimination, in the shape of 
cymbals, pebbles, cylindrical or with cracks; difficulty 
or pain to evacuate; or decreased number of evacuations 
per week (< 3 times) or elimination of bulky stools whi-
ch clog the toilet; or evidences of fecal impaction.
Indications for morphine use and withdrawal, initial do-
ses and dose adjustments were established according to 
the pain treatment protocol used for IOP’s routine. Initial 
morphine dose was oral 0.3 mg/kg every 4 hours.
Patients started treatment with osmotic laxative 24 hours 
after starting with morphine: syrup lactulose solution in 
the presentation of 667 mg/mL, in the dose of 1 mL/kg/
day until the maximum of 60 mL/day.
Fecalomas were systematically investigated through 
physical evaluation or, when needed, with plain abdomi-
nal X-rays. Treatment of fecaloma by fecal desimpaction 
was oral with 3350 polyethylene glycol (PEG 3350 Mu-
vinlax®), 1.5 g/kg/day for three days (maximum dose 
of 100 g/day), or rectal using 10% glycerin solution (10 
mL/day). Rectal desimpaction was indicated when oral 
route was unfeasible due to suspended diet or intoleran-
ce to oral PEG 3350. To be submitted to rectal desimpac-
tion, patients had to have platelet counts above 50,000 
/µL and more than 500 granulocytes /µL.
Laxative intervention outcomes were: 1) evacuation at 
least every two days, with no pain or difficulty to evacu-
ate and 2) lack of fecal impaction during morphine use. 
Efficacy analyses were carried out weekly, according 
to the time patients remained in the study. Patients with 
unsatisfactory therapeutic response received therapeutic 
options, such as the association of other laxatives or re-
placement of morphine by different opioids.
This study was approved by the Ethics Committee, 
Federal University of São Paulo (UNIFESP) under 
number 1502/2006.
RESULTS
Participated in this study 22 patients under morphine and 
meeting eligibility criteria. Mean age of patients was 16.7 
years (5 to 35 years), being 54% males. From evaluated 
patients, 63.6% (14/22) had no possibility of being cured 
and were receiving palliative chemotherapy (Table 1).
At admission, 27.2% of patients had constipation, 
being recommended the use of lactulose (1 mL/kg/
day) for all cases. Two patients needed bisacodyl due 
to intolerance to lactose. After 72 hours, all patients 
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were under laxatives; however, two out of 22 cases had 
fecaloma needing rectal desimpaction with glycerin 
solution and maintenance with bisacodyl (10 mg/day), 
which stimulates bowel movements.
During the first week, 40.9% of patients had constipa-
tion being two with fecalomas. Four out of these nine 
patients did not adhere to prescription and had lower 
lactulose doses. For patients with poor adhesion to 
treatment, lactulose dose was maintained and medical 
recommendations were reinforced. For the other four 
patients evolving with constipation, lactulose dose was 
increased to 2 mL/kg/day.
In the second week, four out of 22 patients left the study 
because morphine was withdrawn. Seven out of 18 re-
maining patients (38.8%) had constipation and four of 
them presented fecaloma, which was desimpacted with 
oral PEG 3350 in two cases and with rectal glycerin so-
lution in two patients. One of these two patients died due 
to progression of baseline disease.
In the third week, morphine was withdrawn for six 
patients. From the 12 patients remaining in follow up, 
83% remained without constipation and 16.6% of them 
had constipation signs.
One refractory patient was identified as not adhering 
to the lactulose treatment and maintenance with PEG 
3350 (0.5 g/kg/Day) was started with good acceptance 
and favorable response in future evaluations. The other 
patient had fecal impaction resolved with rectal glyce-
rin solution. Constipation in this case was considered 
refractory to normal treatment being necessary to repla-
ce the opioid. Patient’s intestinal habit was normalized 
with intradermal fentanyl. One patient died in the third 
week due to baseline disease progression.
During the study period, nine fecaloma episodes were 
diagnosed. Four patients using oral PEG 3350 for fecal 
desimpaction had favorable response before the third 
day of medication and no side effects were observed. 
With regard to oral lactulose used for maintenance, two 
Table 1 – Clinical characteristics of patients (n = 22)
Patient Gender Age (years) Diagnosis Impossible to be Cured
1. M 23 Soft tissue sarcoma Yes
2. M 8 Neuroblastoma Yes
3. M 16 CNS Tumor No
4. F 9 Osteosarcoma Yes
5. M 35 Osteosarcoma Yes
6. F 15 Ewing Tumor No
7. F 7 Soft tissue sarcoma Yes
8. F 13 Soft tissue sarcoma No
9. F 10 Soft tissue sarcoma No
10. M 16 Osteosarcoma Yes
11. M 5 Non-Hodgkin lymphoma No
12. M 13 Wilms Tumor No
13. M 17 CNS Tumor Yes
14. F 14 Osteosarcoma No
15. F 18 Ewing Tumor Yes
16. M 31 Osteosarcoma Yes
17. F 14 Neuroblastoma Yes
18. M 11 Neuroblastoma Yes
19. F 10 Soft tissue sarcoma No
20. M 16 Osteosarcoma Yes
21. M 5 Non-Hodgkin lymphoma No
22. M 13 Wilms Tumor No
CNS = central nervous system; M = male; F = female    
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patients had nausea and the drug was replaced. Table 2 
shows intestinal habits and presence of fecalomas.
Table 2 – Frequency of intestinal constipation and presence of fecalomas (n = 22).
72 hours First Week Second Week Third Week
Intestinal Constipation 6/22(27%) 9/22(41%) 7/18(38.8%) 2/12 (16%)
Presence of fecaloma 2/22 (9%) 2/22(9%) 4/18 (22.2%) 1/12 (8.3%)
Fecal desimpaction 2 rectal 2 oral 2 rectal 1 rectal
2 oral
DISCUSSION
Constipation diagnosis and treatment of cancer pa-
tients have major peculiarities. In these cases, seve-
ral factors may change intestinal habits, such as poor 
food acceptance, dehydration, walking difficulties, use 
of numerous drugs, and clinical and emotional insta-
bility. Among drugs, opioids play a relevant role on 
constipation8-10. These aspects make cancer patients a 
group with differentiated attention needs and any sign 
or symptom of constipation should be considered11,12. 
The complex clinical situation of cancer patients im-
pairs the collection of information to diagnose the cau-
se of intestinal habit changes as well as to determine 
the effective treatment.
Our study group was heterogeneous with different types 
of cancer, different evolution times, simultaneous drugs, 
dose and duration of morphine treatment. Most patients 
(63.6%) had no possibility of being cured and presented 
a large number of intercurrences during the evaluation of 
intestinal habits, such as infections, tumor progression, 
and loss of anal sphincter control. It has to be stressed 
that the clinical status of cancer patients is dynamic, 
both with regard to baseline disease and to existing co-
morbidities7. Constipation secondary to morphine is not 
exception to this rule and our study has observed the 
need for regular and frequent intestinal habit follow up. 
The incidence of constipation is high (40% to 60%) after 
starting with opioids, regardless of the type of morphine 
prescribed, be it immediate or slow release12. However, 
in spite of the frequency and the difficulty of treating it, 
constipation secondary to morphine is poorly valued by 
health professionals13,14. No studies were found in the 
Brazilian literature systematically evaluating the presen-
ce of constipation and the effectiveness of its treatment 
in children under opioids. Studies with adult patients are 
useful15, however they cannot simply be extrapolated as 
paradigm for children and adolescents with their own 
physical, physiological and psychological characteristics.
Although the pain control protocol used in this study 
recommended laxatives when starting with morphine, 
we have observed that only 36.4% of patients adhered 
to prescription. In practice, there has been poor adhe-
sion to laxatives probably due to dysgeusia caused by 
cancer treatment and the need for several simultaneous 
drugs. After the beginning of this study, the adhesion to 
recommended laxatives was very satisfactory and in the 
second and third study weeks only one case of non-adhe-
sion was detected. This result reinforces the need for he-
alth professionals careful attention to diagnose, follow 
up and treat morphine-induced constipation.
Drugs used in this study (laxatives and fecal desimpac-
tion) have followed the recommendations for the treat-
ment of children with chronic severe functional cons-
tipation according to approaches normally adopted in 
Brazil, which are in line with the North-American thera-
peutic guidelines16.
Studies have found that constipation is present between 
the 4th and the 8th day under morphine12. However, in 
our study, probably due to the small sample size, there 
has been no relationship between constipation and the 
time morphine was been used. Constipation secondary 
to morphine was observed in 40.9% of patients in the 
first week, in 38.8% in the second week and in 16.6% 
in the third week.
In spite of the small number of patients, these results 
may be considered similar to the international literatu-
re17,18 and are attributed, in addition to the drugs, to the 
fact that the study was prospective and that specific at-
tention was given to constipation.
It is worth reminding that, according to the literature, 
constipation secondary to morphine affects 70% to 80% 
of terminal patients and is difficult to control7,13,14,19. Our 
study has shown that it was possible to control consti-
pation for most patients. However, the effectiveness of 
the therapy should be analyzed with caution conside-
ring that, for ethical reasons, it would be impossible 
to have a control group. In addition, 40% of patients 
had constipation in spite of preventive measures, su-
ggesting the need for studies with laxatives acting on 
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specific intestinal receptors with higher effectiveness 
and few side effects20-22.
During the study, nine clinical fecaloma were diagnosed 
and fecal desimpaction was a difficult stage of patients’ 
management, generating pain and discomfort. The eli-
mination of impacted stools was achieved with rectal 
drugs or high dose oral laxatives. The acceptance and the 
efficacy of this procedure are critical for the evolution of 
the maintenance treatment with oral laxatives.
Rectal desimpaction should not be done under certain 
clinical conditions, such as leucopenia, low platelet 
count, anal injury, severe immunodepression and wi-
thout patients’ previous consent. In these cases, the op-
tion is high-dose oral laxative which, in our study, was 
successfully used for three times. The effectiveness of 
oral desimpaction with PEG 3350 has been described in 
the literature23. In 2006, the American Society for Pe-
diatric Gastroenterology, Hepatology and Nutrition has 
recommended the use of oral laxatives in high doses for 
fecal desimpaction, however stressing the need for fur-
ther studies in the pediatric age group.
In one patient, constipation was refractory to treatment 
and morphine had to be replaced by intradermal fen-
tanyl in the third week. The replacement of one opioid 
by another should be considered to control refractory or 
unbearable side effects24. The choice of the drug to re-
place morphine varies according to the experience and 
the availability of different medical centers. µ receptor 
agonist opioids have the same action mechanism; howe-
ver, they are different in pharmacodynamics and in the 
affinity for the receptor, which could explain differences 
in analgesia and side effects25.
Nevertheless, the regular use of osmotic and stimulating 
laxatives in adequate doses has improved constipation-
-related symptoms in 50% of patients, which is in line 
with the literature26,27. In three weeks of follow up it was 
possible to evaluate the intestinal habit profile of pa-
tients under morphine, confirming the high incidence of 
constipation, its difficult control and the need for an or-
ganized multidisciplinary protocol to diagnose, prevent 
and treat constipation secondary to morphine.
Early preventive treatment with laxatives, guidance and 
regular follow up may decrease the incidence of seve-
re constipation with fecal impaction. Further controlled 
studies with a higher number of cases are needed to de-
velop effective multiprofessional therapeutic practices to 
decrease the distress of cancer patients under morphine.
CONCLUSION
Constipation was frequent in patients under morphine, 
however, the protocol with specific attention to cons-
tipation has increased patients’ adhesion to laxatives 
and, as a consequence, has decreased the incidence of 
fecalomas.
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